Stephen K. Brannan

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

33h-index8.5kcitations97works12.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Schizophrenia research and treatment(27), Treatment of Major Depression(16), Bipolar Disorder and Treatment(11), Receptor Mechanisms and Signaling(11), Neurological disorders and treatments(10)

Publications97 total

Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial
American Journal of Psychiatry·2026· 2 cited
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon
American Journal of Psychiatry·2025
Assessment of Risk Factors for Vasoplegic Syndrome in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
Cureus·2025Open Access
Measurement of schizophrenia symptoms through speech analysis from PANSS interview recordings
Frontiers in Psychiatry·2025· 2 citedOpen Access
Hydroxocobalamin Dosing Strategies for Vasoplegic Syndrome Post-cardiac Surgery: A Retrospective Cohort Study
Cureus·2025· 1 citedOpen Access
Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Schizophrenia·2025· 1 citedOpen Access
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia
The Journal of Clinical Psychiatry·2025· 8 citedOpen Access
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
Schizophrenia Bulletin·2025· 9 citedOpen Access
Methods to address functional unblinding of raters in CNS trials
Translational Psychiatry·2025Open Access
EFFICACY OF KARXT ON NEGATIVE SYMPTOMS IN ACUTE SCHIZOPHRENIA: AN ANALYSIS OF POOLED DATA FROM 3 TRIALS
The International Journal of Neuropsychopharmacology·2025· 1 citedOpen Access
SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
The International Journal of Neuropsychopharmacology·2025· 4 citedOpen Access
Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia
Schizophrenia Research·2025· 4 citedOpen Access
Response to Commentaries
Schizophrenia Bulletin·2025· 1 citedOpen Access
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials
American Journal of Psychiatry·2024· 35 cited
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Schizophrenia·2024· 23 citedOpen Access
The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia
Frontiers in Psychiatry·2024· 19 citedOpen Access
Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
CNS Spectrums·2024· 1 citedOpen Access
Pooled Analysis of EPS-Like Symptoms in the EMERGENT Program of KarXT in Schizophrenia
CNS Spectrums·2024· 1 citedOpen Access
Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
CNS Spectrums·2024· 1 citedOpen Access
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
Schizophrenia Research·2024· 38 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Andrew Miller(10), Alan Breier(9), A. John Rush(7), Mark S. George(7), Sharon Sawchak(7), Inder Kaul(6), Daniel K. Burns(6), Lauren B. Marangell(5), Harold A. Sackeïm(5), Colin Sauder(5), Kathleen A. Welsh‐Bohmer(5), Helen S. Mayberg(4), Sonia M. Davis(4), Robert H. Howland(4), Mitchel A. Kling(4), Barry R. Rittberg(4), Steven M. Paul(4), Michael W. Lutz(4), Ann M. Saunders(4), Allen D. Roses(4)